Search | Clinical Trials Finder

These results were retrieved from the live ClinicalTrials.gov registry. Filters and sort order apply to this result list.

ClinicalTrials.gov public records Last synced Nov 12, 2026, 10:04 AM EST

All trial information on this site comes from the official ClinicalTrials.gov public API (clinicaltrials.gov/api/v2), run by the U.S. National Library of Medicine. We only display that public information; we do not add opinions, endorsements, or any other intent. Always review the official ClinicalTrials.gov record for the latest information.

Showing 2761–2784 of 3,928 matching trials from the live ClinicalTrials.gov search.

Filters: Condition: HTN Clear all

Conditions: Gestational Hypertension, Hypertension in Pregnancy, Pre-Eclampsia, Superimposed Pre-Eclampsia, Cardiovascular Complication
Interventions: Placebo, Dapagliflozin 10mg Tab; Drug
Lead sponsor: University of Michigan; Other
Eligibility: 18 Years and older · Female only
Enrollment: 200 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2028
U.S. locations: 1
States / cities: Ann Arbor, Michigan

Conditions: Glaucoma, Angle-Closure, Ocular Hypertension
Interventions: Travoprost (0.004%), Latanoprost (0.005%); Drug
Lead sponsor: Alcon Research; Industry
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2000 – 2003
U.S. locations: 1
States / cities: Fort Worth, Texas

Conditions: Pulmonary Hypertension
Interventions: Activity Monitoring; Behavioral
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 230 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2028
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Cognitively Normal Older Adults, Hypertension, Subjective Cognitive Decline, Family History of Alzheimer's Disease
Interventions: Angiotensin II receptor blocker (ARB, losartan) and calcium channel blocker (CCB, amlodipine), Aerobic Exercise Training, Usual Care, Stretching Exercise; Drug · Behavioral · Other
Lead sponsor: University of Texas Southwestern Medical Center; Other
Eligibility: 60 Years to 85 Years
Enrollment: 513 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2022
U.S. locations: 4
States / cities: Kansas City, Kansas • Baton Rouge, Louisiana • St Louis, Missouri + 1 more

Conditions: Pulmonary Arterial Hypertension
Interventions: Treprostinil Inhalation Powder; Drug
Lead sponsor: Mannkind Corporation; Industry
Eligibility: 18 Years to 55 Years
Enrollment: 36 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2018
U.S. locations: 1
States / cities: San Antonio, Texas

Conditions: Hypertension
Interventions: Opt-In Recruitment, Opt-Out Recruitment; Behavioral
Lead sponsor: University of Pennsylvania; Other
Eligibility: 18 Years to 75 Years
Enrollment: 425 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Philadelphia, Pennsylvania

Conditions: Pulmonary Arterial Hypertension
Interventions: inhaled prostacyclin, prostacyclin, subcutaneous and intravenous prostacyclin, oral ERA, oral PDE5 inhibitors; Drug
Lead sponsor: United Therapeutics; Industry
Eligibility: Not listed
Enrollment: 1,333 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2014
U.S. locations: 88
States / cities: Birmingham, Alabama • Mobile, Alabama • Phoenix, Arizona + 65 more

Conditions: Preeclampsia
Interventions: Not listed
Lead sponsor: University of Tennessee; Other
Eligibility: 14 Years to 45 Years · Female only
Enrollment: 87 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2020
U.S. locations: 1
States / cities: Memphis, Tennessee

Conditions: Hypertensive Emergency, Hypertension, Blood Pressure
Interventions: ED-based behavioral intervention, ED usual care plus education; Behavioral
Lead sponsor: Vanderbilt University; Other
Eligibility: 21 Years to 85 Years
Enrollment: 220 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2016 – 2018
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Hypertension
Interventions: Remote Blood Pressure Monitoring + Telehealth, Usual care; Other
Lead sponsor: University of Alabama at Birmingham; Other
Eligibility: 18 Years and older
Enrollment: 24 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2026
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Pre-Eclampsia, Obesity, Gestational Diabetes, Gestational Hypertension
Interventions: Women's Health Delaware Food Farmacy, Usual Standard of Care; Other
Lead sponsor: Christiana Care Health Services; Other
Eligibility: 18 Years and older · Female only
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2025
U.S. locations: 1
States / cities: Newark, Delaware

Conditions: Hypertension, Mild Cognitive Impairment
Interventions: Candesartan, Lisinopril; Drug
Lead sponsor: Emory University; Other
Eligibility: 55 Years and older
Enrollment: 176 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2018
U.S. locations: 1
States / cities: Atlanta, Georgia

Conditions: Difficult to Control Hypertension
Interventions: MANP, Placebo Matched control; Drug · Other
Lead sponsor: E-Star BioTech, LLC; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 120 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2024 – 2027
U.S. locations: 23
States / cities: Little Rock, Arkansas • Lake Forest, California • Westlake Village, California + 19 more

Conditions: Pulmonary Arterial Hypertension
Interventions: Beraprost Sodium 314d Modified Release Tablets, Placebo; Drug
Lead sponsor: Lung Biotechnology PBC; Industry
Eligibility: 18 Years to 80 Years
Enrollment: 273 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2019
U.S. locations: 69
States / cities: Birmingham, Alabama • Beverly Hills, California • Fountain Valley, California + 55 more

Conditions: Hypertension, Cardiovascular Diseases, Vascular Diseases
Interventions: HTN Educational Video, Visual Echocardiogram Image Clips, Mobile Health and Remote BP monitoring, Post-Acute Care HTN Transition consultation (PACHT-c); Other
Lead sponsor: University of Illinois Chicago; Other
Eligibility: 18 Years to 75 Years
Enrollment: 574 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2023
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Hypertension
Interventions: Placebo, lorundrostat Dose 1, lorundrostat Dose 2; Drug
Lead sponsor: Mineralys Therapeutics Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 1,083 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2025
U.S. locations: 87
States / cities: Alexander City, Alabama • Birmingham, Alabama • Foley, Alabama + 74 more

Conditions: Chronic Disease, Neoplasm, Cardiovascular Disease, Pulmonary Disease, Chronic Obstructive, Diabetes Mellitus, Hypertension
Interventions: Family-supported, Standard Telephone counseling; Behavioral
Lead sponsor: US Department of Veterans Affairs; Federal
Eligibility: 18 Years and older
Enrollment: 471 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2012
U.S. locations: 1
States / cities: Durham, North Carolina

Conditions: Portal Hypertension
Interventions: Transjugular Intrahepatic Portosystemic Shunt; Procedure
Lead sponsor: University of Kansas Medical Center; Other
Eligibility: 18 Years and older
Enrollment: 30 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2017 – 2021
U.S. locations: 1
States / cities: Kansas City, Kansas

Conditions: Salt Sensitivity of Blood Pressure, Hypertension
Interventions: High Salt Diet, Low Salt Diet; Dietary Supplement
Lead sponsor: Vanderbilt University Medical Center; Other
Eligibility: 50 Years to 70 Years
Enrollment: 281 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2025
U.S. locations: 2
States / cities: Birmingham, Alabama • Chicago, Illinois

Conditions: Hypertension
Interventions: Aliskiren, Hydrochlorothiazide; Drug
Lead sponsor: Novartis; Industry
Eligibility: 18 Years and older
Enrollment: 532 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2008 – 2009
U.S. locations: 1
States / cities: East Hanover, New Jersey

Conditions: Ocular Hypertension
Interventions: Loteprednol etabonate ophthalmic suspension 0.5%, Loteprednol etabonate (0.5%) and tobramycin (0.3%).; Drug
Lead sponsor: Allergan; Industry
Eligibility: 18 Years and older
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2009
U.S. locations: 1
States / cities: Maclean, Virginia

Conditions: Hypertension
Interventions: Eucommia; Dietary Supplement
Lead sponsor: Pennington Biomedical Research Center; Other
Eligibility: 18 Years to 70 Years
Enrollment: 30 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2007 – 2013
U.S. locations: 1
States / cities: Baton Rouge, Louisiana

Conditions: Pulmonary Hypertension
Interventions: Pulmonary artery pressure measurements; Other
Lead sponsor: Northwestern University; Other
Eligibility: 18 Years to 80 Years
Enrollment: 90 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Chicago, Illinois

Conditions: Pulmonary Arterial Hypertension, Chronic Thromboembolic Pulmonary Hypertension
Interventions: Non-invasive hemodynamic measurements; Device
Lead sponsor: University of California, Los Angeles; Other
Eligibility: 18 Years and older
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2024
U.S. locations: 1
States / cities: Los Angeles, California

Search by objective public record fields.

A Randomized, Placebo-controlled Trial of DAPAgliflozin (DAPA) for Cardiovascular Risk Reduction in the Postpartum Period of Hypertensive Pregnancies (HP)

A Safety and Efficacy Study of Travoprost 0.004% Compared to Latanoprost 0.005% in Patients With Chronic Angle-Closure Glaucoma

Activity Monitoring in Pulmonary Hypertension

Risk Reduction for Alzheimer's Disease

Pharmacokinetics, Safety and Tolerability of Treprostinil Inhalation Powder in Healthy Normal Volunteers

SupportBP 2.0:Behavioral Science and Enrollment in Remote Monitoring for Hypertension Management

Study of Incidence of Respiratory Tract AEs in Patients Treated With Tyvaso® Compared to Other FDA Approved PAH Therapies

sFlt-1:PlGF Ratio in Diagnosing Superimposed Preeclampsia

A ED-based Intervention to Improve Antihypertensive Adherence

Monitoring Blood Pressure at Home

Evaluating the Effectiveness of a Food is Medicine Community Health Worker Program for Pregnant Women

CAndesartan vs LIsinopril Effects on the BRain

To Evaluate the Safety and Efficacy of MANP in Subjects With Difficult to Control/ Resistant Hypertension

Beraprost-314d Added-on to Tyvaso® (BEAT)

Targeting of UnControlled Hypertension in Emergency Department

Efficacy and Safety of Lorundrostat in Subjects With Uncontrolled and Resistant Hypertension

Family-supported Smoking Cessation for Chronically Ill Veterans

Ultrasound Elastography Assessment of Spleen and Liver Stiffness Before and After Transjugular Intrahepatic Portosystemic Shunt (TIPS) Procedure

CARDIA-Salt Sensitivity of Blood Pressure (SSBP)

Aliskiren Plus HCTZ Compared to Aliskiren in Metabolic Syndrome Patients With Stage 2 Systolic Hypertension

A Retrospective Evaluation of the Intraocular Pressure Spikes With Loteprednol and Loteprednol/Tobramycin

Standardized Eucommia Extract in the Treatment of Hypertension

Contrast Enhanced PA Pressure Measurements

Non-Invasive Measurement of Cardiac Output and Stroke Volume in PAH/CTEPH